No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Renascience ETC [Stocks with allure seen from Volume changes]
Stock closing prices compared to the previous day Volume *<2480>* Sysloco 1,494,244,217,300 *<7235>* Toh Radiator 987,112,881,000 *<4512>* Wakamoto 319,165,211,200 *<3538>* Will Plus H 994,215,6600 *<4889>* Renascience 124,613,068,61800 *<130A>* VIS 860,406,7900 *<7214>* GMB 958,311,03500 *<302A>* B-Style HD 150,015,93910
Spot information on individual stocks (2)
Shin-Ohashi Science <2395.T> rebounds for the first time in four days. Nomura Securities upgraded the stock from "neutral" to "Buy" and raised the Target Price to 2080 yen (previously 1460 yen). Metapla <3350.T> sharply declined. U.S. President Trump signed an executive order to establish a strategic reserve of Bitcoin, but the expectation for new purchases has decreased because the confiscated Bitcoin owned by the federal government would be used as reserves. This led to a significant drop in Cryptos.
Softness and the decline in US stocks weigh down [Emerging Markets Individual Stock Global Strategy].
[Emerging Markets Individual Stock Global Strategy] Today's Emerging Markets are expected to show a weak performance. In the U.S. stock market yesterday, October 6th, the Dow Inc fell by 427.51 points (-0.99%) to 42,579.08. Concerns over economic slowdown intensified due to the widening trade deficit, while selling related to heightened friction with other countries weighed on stock prices. Meanwhile, President Trump announced some reductions in tariffs on Mexico and Canada, but there was little recovery, and the market finished in the lower range. Today, selling will dominate the Emerging Markets.
PSS, Renascience and others.
From the 6th, the number of shares to be delivered for the large exercise of subscription rights for Mobcast HD's 35th round (with exercise price adjustment clauses) will be 2.1 million shares. Renascience <4889> achieved the primary endpoint in the validation clinical performance study of Artificial Intelligence (AI) predicting insulin dosage for diabetic patients. PSS <7707> will conduct a Share Buyback, with a maximum of 440,600 shares (1.59% of the outstanding shares) to be purchased on the 7th via ToSTNeT-3.
Renascient sharply rises as the phase 3 trial of the PAI-1 inhibitor for malignant melanoma begins.
Renascience <4889.T> surged, briefly rising by 151 yen to reach 1579 yen. At noon on the 18th, the company announced that the administration of its PAI-1 inhibitor "RS5614" to the first subject began at Tohoku University Hospital for the phase 3 trial of malignant melanoma, leading to positive speculation. This phase 3 trial targets 124 patients with unresectable malignant melanoma and aims to verify the efficacy and safety of the combination of nivolumab and "RS5614."
Renascience: Summary of financial results for the 3rd quarter of the fiscal year ending March 31, 2025 [Japanese GAAP] (unconsolidated)